- Aditxt's (ADTX, Financial) virtual event on May 2, 2025, to feature Mayo Clinic's Dr. Charles Howe on preclinical study results.
- Dr. Howe will discuss findings related to ADI-100â„¢, a therapeutic candidate by Aditxt's subsidiary Adimuneâ„¢.
- Key figures from Aditxt, including CIO Dr. Shahrokh Shabahang, will participate.
Aditxt, Inc. (ADTX), a social innovation platform focused on accelerating health innovations, has announced a significant virtual event scheduled for May 2, 2025. The company's weekly update will feature Dr. Charles Howe from Mayo Clinic's Neuroimmunology Department. Dr. Howe, who directs research at the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, will share insights from a recent preclinical study on ADI-100â„¢, the lead therapeutic candidate from Aditxt's wholly owned subsidiary, Adimuneâ„¢.
The virtual event is set to take place at 11:30 a.m. ET via Zoom and will include other notable speakers such as Dr. Shahrokh Shabahang, Aditxt's Chief Innovation Officer, and Dr. Friedrich Kapp, Co-CEO of Adimuneâ„¢.
ADI-100â„¢ represents a pioneering approach in the treatment of autoimmune diseases, using apoptotic DNA immunotherapy to restore immune tolerance. This investigational therapy seeks to retrain the immune system without the need for traditional immunosuppression, potentially offering significant safety and efficacy benefits.
Aditxt, Inc. continues to push forward with its mission to make promising health innovations possible, with programs targeted at immune health and precision health, and plans to expand into public health and women's health.
